PBAC's latest decision on Abacavir sulfate with lamivudine: Recommended (2005). Considered for Treatment of HIV infection in combination antiretroviral therapy in patients over 12 years of age weighing 40 kg or more with CD4 cell counts less than 500 per cubic millimetre or viral load greater than 10,000 copies per mL.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
Patients over 12 years of age weighing 40 kg or more with CD4 cell counts less than 500 per cubic millimetre or viral load greater than 10,000 copies per mL
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Non-inferiority
Key trials
CAL30001, ESS30008
Comparator
abacavir co-administered with lamivudine as single agents